Literature DB >> 16972162

Using GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLI.

Leah Kleinman1, Anne Kilburg, Gerardo Machnicki, Randall Faull, Rowan Walker, Ramesh Prasad, Patrice Ambuehl, Udo Bahner, Mary Kay Margolis.   

Abstract

INTRODUCTION: Gastrointestinal (GI) side-effects occur frequently as a result of immunosuppressant regimens used in renal transplant patients. Little effort has been made to quantify the impact of these side-effects on patients' health-related quality of life and symptom severity.
OBJECTIVE: To assess the psychometric characteristics of two GI-specific outcome instruments (the Gastrointestinal Rating Scale (GSRS) and the Gastrointestinal Quality of Life Index (GIQLI)) for use in post-renal transplant patients.
METHODS: Cross-sectional study conducted at 5 clinical centers in 4 countries. Patients were required to be on mycophenolate mofetil and a calcineurin inhibitor. Patients completed the GSRS, GIQLI and two generic instruments (the Psychological General Well-Being Index and the EQ-5D) at one timepoint. Reliability, construct and known groups validity were assessed.
RESULTS: In general the GSRS and the GIQLI demonstrated Cronbach's alphas higher than 0.70. The GIQLI was moderately to highly correlated with the PGWB and EQ-5D. Correlations among the GSRS and generic instruments were slightly lower. The GSRS and GIQLI both distinguished between patients with and without GI complaints (all p<0.05).
CONCLUSIONS: The GSRS and the GIQLI are appropriate for use in a post-renal transplant population. Scores on both instruments demonstrated significant differences between renal transplant patients with GI complications and without GI complications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972162     DOI: 10.1007/s11136-006-0053-5

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  23 in total

Review 1.  Assessing health status and quality-of-life instruments: attributes and review criteria.

Authors:  Neil Aaronson; Jordi Alonso; Audrey Burnam; Kathleen N Lohr; Donald L Patrick; Edward Perrin; Ruth E Stein
Journal:  Qual Life Res       Date:  2002-05       Impact factor: 4.147

Review 2.  Measuring quality of life.

Authors:  M E Jenney; S Campbell
Journal:  Arch Dis Child       Date:  1997-10       Impact factor: 3.791

3.  Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.

Authors:  J Miller; R Mendez; J D Pirsch; S C Jensik
Journal:  Transplantation       Date:  2000-03-15       Impact factor: 4.939

4.  Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection.

Authors:  A O Ojo; H U Meier-Kriesche; J A Hanson; A B Leichtman; D Cibrik; J C Magee; R A Wolfe; L Y Agodoa; B Kaplan
Journal:  Transplantation       Date:  2000-06-15       Impact factor: 4.939

5.  A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.

Authors:  J D Pirsch; J Miller; M H Deierhoi; F Vincenti; R S Filo
Journal:  Transplantation       Date:  1997-04-15       Impact factor: 4.939

6.  Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.

Authors: 
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

7.  Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?

Authors:  E Dimenäs; H Glise; B Hallerbäck; H Hernqvist; J Svedlund; I Wiklund
Journal:  Scand J Gastroenterol       Date:  1993-08       Impact factor: 2.423

8.  The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation.

Authors:  Ronald P Pelletier; Baris Akin; Mitchell L Henry; Ginny L Bumgardner; Elmahdi A Elkhammas; Amer Rajab; Ronald M Ferguson
Journal:  Clin Transplant       Date:  2003-06       Impact factor: 2.863

9.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

Authors: 
Journal:  Transplantation       Date:  1996-04-15       Impact factor: 4.939

10.  A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

Authors:  T H Mathew
Journal:  Transplantation       Date:  1998-06-15       Impact factor: 4.939

View more
  11 in total

1.  Microbiological diagnosis of severe diarrhea in kidney transplant recipients by use of multiplex PCR assays.

Authors:  Jean-François Coste; Vincent Vuiblet; Betoul Moustapha; Alexis Bouin; Sylvie Lavaud; Olivier Toupance; Alexis de Rougemont; Lucie Benejat; Francis Megraud; Aurore Wolak-Thierry; Isabelle Villena; Cathy Chemla; Elisabeth Le Magrex; Christophe de Champs; Laurent Andreoletti; Philippe Rieu; Nicolas Leveque
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

2.  Characterization of Gastrointestinal Symptom Type and Severity in Parkinson's Disease: A Case-Control Study in an Australian Cohort.

Authors:  Jade E Kenna; Megan C Bakeberg; Anastazja M Gorecki; Alfred Chin Yen Tay; Samantha Winter; Frank L Mastaglia; Ryan S Anderton
Journal:  Mov Disord Clin Pract       Date:  2021-01-05

Review 3.  Outcomes after kidney transplantation, let's focus on the patients' perspectives.

Authors:  Yiman Wang; Jaapjan D Snoep; Marc H Hemmelder; Koen E A van der Bogt; Willem Jan W Bos; Paul J M van der Boog; Friedo W Dekker; Aiko P J de Vries; Yvette Meuleman
Journal:  Clin Kidney J       Date:  2021-01-20

4.  A pilot study on area under curve of mycophenolic acid as a guide for its optimal use in renal transplant recipients.

Authors:  S C Sarangi; K H Reeta; S K Agarwal; T Kaleekal; S Guleria; Y K Gupta
Journal:  Indian J Med Res       Date:  2012       Impact factor: 2.375

5.  A multicenter experience with generic mycophenolate mofetil conversion in stable liver transplant recipients.

Authors:  Jong Man Kim; Choon Hyuck David Kwon; Ik Jin Yun; Kwang-Woong Lee; Hee Chul Yu; Kyung-Suk Suh; Jae-Won Joh; Baik Hwan Cho
Journal:  Ann Surg Treat Res       Date:  2014-03-25       Impact factor: 1.859

6.  Validity and reliability of a novel immunosuppressive adverse effects scoring system in renal transplant recipients.

Authors:  Calvin J Meaney; Ziad Arabi; Rocco C Venuto; Joseph D Consiglio; Gregory E Wilding; Kathleen M Tornatore
Journal:  BMC Nephrol       Date:  2014-06-12       Impact factor: 2.388

Review 7.  Measurement properties of patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease: A systematic review.

Authors:  Olalekan Lee Aiyegbusi; Derek Kyte; Paul Cockwell; Tom Marshall; Adrian Gheorghe; Thomas Keeley; Anita Slade; Melanie Calvert
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

8.  Gastrointestinal (GI)-Specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: results from a South American cohort.

Authors:  Gerardo Machnicki; Jacqueline Pefaur; Luis Gaite; Ana M Linchenco; Clemente Raimondi; Ruben Schiavelli; Alcira Otero; Mary Kay Margolis
Journal:  Health Qual Life Outcomes       Date:  2008-07-21       Impact factor: 3.186

9.  Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study.

Authors:  Bernhard Manger; Falk Hiepe; Matthias Schneider; Margitta Worm; Peter Wimmer; Eva-Maria Paulus; Andreas Schwarting
Journal:  Clin Exp Gastroenterol       Date:  2015-07-21

10.  Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes.

Authors:  Rocco C Venuto; Calvin J Meaney; Shirley Chang; Nicolae Leca; Joseph D Consiglio; Gregory E Wilding; Daniel Brazeau; Aijaz Gundroo; Neha Nainani; Sarah E Morse; Louise M Cooper; Kathleen M Tornatore
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.